Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

44,651 stories, page 619 of 745

Advanced search

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

DEA, FDA Testify on First Day of Hearing on Marijuana Rescheduling

FilterOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical company closing Birmingham facility

AL.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Buzz On Experimental Drug For Bowel Disease Sets This Biotech Stock Soaring 40%

NDTV ProfitOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

FDA lets Philip Morris market Zyn nicotine pouches as less harmful than cigarettes

CNBCOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com

Investing.com South AfricaOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

BenzingaOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection

PharmTech.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Many pharmaceutical active ingredients can switch to PFAS-free alternatives

News-MedicalOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Anthropic Livestreams AI for Science Pitch as No AI Drug Has Won FDA Approval

Tech TimesOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug

marketscreener.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

FDA Selects Seven Pharmaceutical Companies for PreCheck Supply Chain Pilot Program

geneonline.comOriginal source

🌍Jul 1discoverynews.google.comTier 2 · Trade media

EAN 2026: New Fintepla data in Dravet Syndrome and LGS

Pharmaceutical TechnologyOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Pelabresib from MorphoSys AG - late-stage blood cancer drug reshapes the pipeline

AD HOC NEWSOriginal source

🇺🇸Jul 1CDMOagcbio.comTier 2 · Direct publisher

AGC Biologics Expands to Fill-Finish in U.S. Through Strategic Partnership with Pyramid Pharma Services

AGC BiologicsOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

RFK Jr.’s plan to boost peptide access just got more complicated

The Washington PostOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Stoke completes Phase 3 enrollment for Dravet drug study

grafa.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Abivax Shares Surge Over 40% as Obefazimod Data Eases Cancer Fears Ahead of FDA Filing

finance.biggo.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Seven Companies Selected for FDA Pilot to Strengthen US Drug Supply Chain

Pharmaceutical CommerceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Imviva Biotech Gains FDA IDE Authorization for clonoSEQ Assay in TENACITY-01 Clinical Trial

citybizOriginal source

🇺🇸Jun 30Researchatlasventure.comTier 2 · Direct publisher

Two Roads Diverged

Atlas VentureOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD

Ophthalmology TimesOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Why Is Unicycive Therapeutics Stock Falling Tuesday?

BenzingaOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

2 Pa. pharmaceutical facilities to close, lay off 173 people

PennLive.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Binghamton University research study advances treatment for Duchenne muscular dystrophy

Binghamton UniversityOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Federal Drug Research Profits: Taxpayers Get Little Return

Legis1Original source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Medical journal retracts Tavneos pivotal study article, complicating Amgen’s defense effort

Fierce PharmaOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

BIO outshines World Cup as biotech celebrates 50th anniversary with a ‘call to action’

BioSpaceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder.

BitgetOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data.

BitgetOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Abivax rebounds from stock drop with safety data for much-hyped colitis prospect

Fierce BiotechOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Unicycive gets FDA CRL for OLC kidney drug application

grafa.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Unicycive gets FDA CRL for OLC kidney drug application

grafa.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Baltimore Ravens TE Mark Andrews Reveals New Partnership Biotech Company to Raise Awareness

Sports IllustratedOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics

PR NewswireOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

FDA Chooses 7 Companies for PreCheck Pilot

PharmTech.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

US FDA declines to approve Unicycive's kidney disease drug

ReutersOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Vistagen fails another phase 3 social anxiety trial but spies path to market

Fierce BiotechOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Investors double down on Bain-backed startup

statnews.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Documentation Reliability Across Contractors: A Quality Systems Approach

PharmTech.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

24/7 Wall St.Original source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Medicare Obesity Drug Coverage Puts These 3 Biotech Stocks In Focus

simplywall.stOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?

Yahoo Finance UKOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Pharma VoiceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

Yahoo FinanceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

Yahoo FinanceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

Yahoo FinanceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Yahoo FinanceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?

Yahoo FinanceOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Unicycive turned away by FDA again over manufacturer’s plant shortfalls

Fierce PharmaOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Trinity Biotech’s AI cooling unit wins Open Compute Project backing

Stock TitanOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Crews respond to fire, hazmat situation at Cherry Hill pharmaceutical facility

NBC10 PhiladelphiaOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Simplified C-glycosides synthesis could transform diabetes drug manufacturing

European Pharmaceutical ReviewOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

US FDA declines to approve Unicycive’s drug to treat elevated phosphate levels in dialysis patients

101 WIXXOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)

Yahoo FinanceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Telitacicept Improves Clinical Response but Increases Infection and Hypogammaglobulinemia Risk in Adults with Active SLE: Phase 3 Trial Results

Vera HealthOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Telitacicept Improves Clinical Response but Increases Infection and Hypogammaglobulinemia Risk in Adults with Active SLE: Phase 3 Trial Results

Vera HealthOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised

Stock TitanOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com

Investing.com AustraliaOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com

Investing.com AustraliaOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

FDA Issues CRL for Oxylanthanum Carbonate

ConexiantOriginal source